Group One Trading
SYRE icon

Group One Trading’s Spyre Therapeutics SYRE Stock Holding History

Group One Trading’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-100
Closed -$3.28K – 8714
2025
Q4 		$3.28K Buy
+100
New +$2.61K ﹤0.01% 7363
2024
Q2 		– Sell
-2,000
Closed -$75.9K – 7465
2024
Q1 		$75.9K Hold
2,000
– – ﹤0.01% 4379
2023
Q4 		$43K Sell
2,000
-600
-23% -$8.27K ﹤0.01% 5181
2023
Q3 		$31.9K Buy
+2,600
New +$34.4K ﹤0.01% 5499
2022
Q3 		– Sell
-84
Closed -$1K – 8238
2022
Q2 		$1K Buy
84
+72
+600% +$2.52K ﹤0.01% 7623
2022
Q1 		$1K Sell
12
-192
-94% -$16.1K ﹤0.01% 7878
2021
Q4 		$24K Buy
+204
New +$32.2K ﹤0.01% 6873
2021
Q3 		– Sell
-200
Closed -$35K – 8770
2021
Q2 		$35K Buy
200
+188
+1,567% +$34.2K ﹤0.01% 6859
2021
Q1 		$2K Buy
12
+4
+50% +$767 ﹤0.01% 7403
2020
Q4 		$2K Buy
8
+4
+100% +$829 ﹤0.01% 6273
2020
Q3 		$1K Buy
+4
New +$740 ﹤0.01% 5958

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Group One Trading's SYRE Position: Q1 2026 in Review

Group One Trading increased its Spyre Therapeutics (SYRE) stake by 125% in Q1 2026, buying an estimated $18.9K and bringing the position to 901 shares worth $45.4K. The position accounts for ﹤0.01% of the portfolio, ranked #5329.

Group One Trading first reported a position in SYRE in Q3 2020 and has held it in 13 quarters since. 197 funds tracked by Wall St. Rank hold SYRE as of Q1 2026.

  • Group One Trading held 901 shares of Spyre Therapeutics worth $45.4K as of Q1 2026.
  • Group One Trading bought 501 Spyre Therapeutics shares in Q1 2026, an estimated $18.9K.
  • Spyre Therapeutics made up ﹤0.01% of Group One Trading's portfolio in Q1 2026, its #5329 holding.
  • Group One Trading first reported a position in Spyre Therapeutics in Q3 2020 and has held it in 13 quarters since.
  • 197 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.